158 related articles for article (PubMed ID: 18461656)
1. Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China.
Chen XZ; Jiang K; Hu JK; Zhang B; Gou HF; Yang K; Chen ZX; Chen JP
World J Gastroenterol; 2008 May; 14(17):2715-22. PubMed ID: 18461656
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens.
Norum J; Angelsen V
J Chemother; 1995 Oct; 7(5):455-9. PubMed ID: 8596132
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
4. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
Kim YJ; Goh PG; Kim ES; Lee SY; Moon HS; Lee ES; Sung JK; Kim SH; Lee BS; Jeong HY
Korean J Gastroenterol; 2011 Dec; 58(6):311-7. PubMed ID: 22198228
[TBL] [Abstract][Full Text] [Related]
6. The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience.
Ben Aharon I; Purim O; Kundel Y; Brenner R; Gordon N; Sulkes A; Brenner B
Anticancer Drugs; 2012 Mar; 23(3):313-20. PubMed ID: 22241172
[TBL] [Abstract][Full Text] [Related]
7. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
[TBL] [Abstract][Full Text] [Related]
8. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Hofheinz RD; Hartung G; Samel S; Hochhaus A; Pichlmeier U; Post S; Hehlmann R; Queisser W
Onkologie; 2002 Jun; 25(3):255-60. PubMed ID: 12119460
[TBL] [Abstract][Full Text] [Related]
9. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting.
Kilickap S; Yalcin S; Ates O; Tekuzman G
Hepatogastroenterology; 2011; 58(105):208-12. PubMed ID: 21510316
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer.
Zhou K; Wen F; Zhang P; Zhou J; Chen H; Zheng H; Yang Y; Li Q
Clin Transl Oncol; 2017 Sep; 19(9):1117-1124. PubMed ID: 28353006
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.
Chen XL; Chen XZ; Yang C; Liao YB; Li H; Wang L; Yang K; Li K; Hu JK; Zhang B; Chen ZX; Chen JP; Zhou ZG
PLoS One; 2013; 8(4):e60320. PubMed ID: 23593191
[TBL] [Abstract][Full Text] [Related]
12. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).
Zaanan A; Samalin E; Aparicio T; Bouche O; Laurent-Puig P; Manfredi S; Michel P; Monterymard C; Moreau M; Rougier P; Tougeron D; Taieb J; Louvet C
Dig Liver Dis; 2018 Apr; 50(4):408-410. PubMed ID: 29409778
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
14. Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.
Zhou KR; Cheng A; Ng WT; Kwok TY; Yip EY; Yao R; Leung PY; Lee VW
J Med Econ; 2017 May; 20(5):541-548. PubMed ID: 28277030
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.
Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I
Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516
[TBL] [Abstract][Full Text] [Related]
16. Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
Pourghasemian M; Danandeh Mehr A; Molaei M; Habibzadeh A
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2337-2341. PubMed ID: 32856863
[TBL] [Abstract][Full Text] [Related]
17. [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Wang ZH; Guo J; Chen Z; Li CZ; Sheng LJ; Zhou DG; Liu B; Liu J; Wang QC; Zhang EN
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):389-91. PubMed ID: 18953843
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Zeng H; Wang C; Song LY; Jia SJ; Zeng X; Liu Q
BMJ Open; 2022 Nov; 12(11):e060983. PubMed ID: 36375981
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
